Floatz logo

Serplulimab

Non Small Cell Lung Cancer

Tang-Du Hospitalmonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
65/ 100

Competitive context

203 Active assets in the Non Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Pyrotinib
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 4BB
Vinorelbine
Intergroupe Francophone de Cancerologie Thoracique
Phase 4BB
Osimertinib
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 4BB
Tislelizumab
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 4BB
rc48-adc
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

Serplulimab is also rated in:

ImmunotherapyDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →